Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Morbillivirus Infection

The impact of morbilliviruses on both human and animal health has driven extensive research into developing effective vaccines and therapies. Our company is committed to advancing the science of vaccine and therapy development, providing innovative solutions to protect against these devastating diseases.

Introduction to Morbillivirus Infection

Morbilliviruses are a genus of viruses within the family Paramyxoviridae, order Mononegavirales, known for their significant impact on both human and animal health. These enveloped, non-segmented, negative-sense RNA viruses exhibit a wide host range, infecting species from various mammalian orders. The genus includes the canine distemper virus (CDV) and several other species that affect marine mammals and wildlife. Morbilliviruses are responsible for a spectrum of diseases, from respiratory infections and encephalitis to systemic diseases with potential fatal outcomes.

Fig.1 The important milestones in the canine morbillivirus (CDV) research timeline. (Karki M., et al., 2022)

Vaccine Development for Morbillivirus Infection

Recombinant Vector Vaccines

Recombinant vector vaccines employ non-replicating viral vectors to deliver specific antigens of the morbillivirus. A recombinant canine distemper vaccine using a modified vaccinia virus Ankara (MVA) vector has shown promise in preclinical trials, demonstrating the potential to protect against CDV without causing disease.

Subunit Vaccines

A subunit vaccine candidate for CDV, focusing on the hemagglutinin (H) protein, has been developed and is currently undergoing evaluation. The use of this protein, which plays a crucial role in viral attachment and entry, is expected to elicit a strong and protective immune response.

Therapeutics Development for Morbillivirus Infection

Antiviral Drugs

The development of antiviral drugs against morbilliviruses has been challenging due to the lack of targeted therapies. However, recent studies have identified nitazoxanide, a thiazolide with broad-spectrum antiviral activity, as a potential therapeutic option. Nitazoxanide has shown in vitro activity against both measles and canine distemper viruses, inhibiting viral replication and spread.

Gene Therapies

Gene therapies, such as RNA interference (RNAi), have emerged as a promising approach for morbillivirus therapeutics. Short hairpin RNAs (shRNAs) can be designed to target and degrade specific viral RNA sequences, effectively inhibiting viral replication. This approach has shown significant reduction in viral loads in cell culture models.

Our Services

At our company, we are committed to being the trusted partner in the fight against Morbillivirus infections. To that end, we offer a comprehensive suite of research and development services to support scientists and the global pharmaceutical industry in their efforts to combat these formidable pathogens.

Our Morbillivirus research capabilities span the entire drug and vaccine development spectrum, including:

Virology and Molecular Biology: Our state-of-the-art facilities and experienced research teams specialize in the isolation, characterization, and genetic analysis of Morbillivirus strains, enabling the identification of novel targets and the development of targeted interventions.
Vaccine Development: From antigen design and formulation optimization to preclinical evaluation, our vaccine development services cover every stage of the pipeline, ensuring the delivery of safe and effective Morbillivirus vaccine candidates.
Therapeutic Discovery and Optimization: Our drug discovery platforms, including high-throughput screening and rational drug design, are dedicated to identifying and refining potent Morbillivirus inhibitors, with a focus on targeting critical viral proteins and host factors.

Vaccine Development

Therapeutic Development

Disease Models

SLAM-blind Viruse Infection Models
Nectin-4 blind Viruse Infection Models

Optional species: ferret, dog, and non-human primate animals

By leveraging the latest scientific advancements, maintaining a relentless focus on delivering tangible results, and fostering strategic partnerships, we are confident in our ability to make a profound impact in the fight against these formidable viruses. If you are interested in our services, please feel free to contact us.

References

Karki, Monu, Kaushal Kishor Rajak, and Rabindra Prasad Singh. "Canine morbillivirus (CDV): a review on current status, emergence and the diagnostics." Virusdisease 33.3 (2022): 309-321.
Stelitano, Debora, et al. "Antiviral activity of nitazoxanide against Morbillivirus infections." Journal of Virus Eradication 9.4 (2023): 100353.
de Carvalho, Otávio Valério, et al. "Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus." BMC veterinary research 16 (2020): 1-17.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.